Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study

Cancer Communications

Table 3 Multivariate analysis of prognostic factors for OS and PFS of patients with DLBCL

Variate	OS			PFS
Variate	HR	95% CI	P	HR	95% CI	P
Age	1.38	1.69–9.40	< 0.01	0.39	0.87–2.51	0.15
Clinical stage	− 0.39	0.22–2.06	0.57	0.69	1.23–3.23	0.01
B symptoms	− 0.93	0.12–1.35	0.63	0.45	0.97–2.56	0.07
Spleen involvement	− 0.05	0.24–3.87	0.95	0.34	0.74–2.67	0.30
IPI	1.01	0.59–12.70	0.20	0.02	0.51–2.04	0.96
LDH	0.29	0.49–3.67	0.57	0.24	0.76–2.15	0.35
β2-MG	0.02	0.33–3.18	0.98	–
Rituximab	− 0.13	0.34–2.26	0.80	–
CR after first-line chemotherapy	− 1.54	0.09–0.49	< 0.01	− 0.24	0.48–1.27	0.33
PD-L1 expression in tumor cells	1.40	1.61–10.23	< 0.01	0.46	1.00–2.51	0.05

IPI international prognostic index, LDH lactate dehydrogenase, β2-MG β2-microglobulin, CR complete remission, PD-L1 programmed cell death ligand 1, – not included